LEVOLET Drug Patent Profile
When do Levolet patents expire, and when can generic versions of Levolet launch?
Levolet is a drug marketed by Genus Lifesciences and is included in one NDA. There are two patents protecting this drug.
The generic ingredient in LEVOLET is levothyroxine sodium. There is one drug master file entry for this compound. Fifty suppliers are listed for this compound. Additional details are available on the levothyroxine sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Levolet
A generic version of LEVOLET was approved as levothyroxine sodium by MYLAN on June 5th, 2002.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for LEVOLET?
- What are the global sales for LEVOLET?
- What is Average Wholesale Price for LEVOLET?
Summary for LEVOLET
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 73 |
| Clinical Trials: | 2 |
| Patent Applications: | 2,604 |
| DailyMed Link: | LEVOLET at DailyMed |
Recent Clinical Trials for LEVOLET
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Dr. Reddy's Laboratories Limited | Phase 4 |
| Dr. Reddy's Laboratories Limited |
US Patents and Regulatory Information for LEVOLET
LEVOLET is protected by two US patents.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genus Lifesciences | LEVOLET | levothyroxine sodium | TABLET;ORAL | 021137-001 | Jun 6, 2003 | AB1,AB2,AB3,AB4 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Genus Lifesciences | LEVOLET | levothyroxine sodium | TABLET;ORAL | 021137-010 | Jun 6, 2003 | AB1,AB2,AB3,AB4 | RX | No | No | 10,406,108 | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| Genus Lifesciences | LEVOLET | levothyroxine sodium | TABLET;ORAL | 021137-005 | Jun 6, 2003 | AB1,AB2,AB3,AB4 | RX | No | No | 10,231,931 | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| Genus Lifesciences | LEVOLET | levothyroxine sodium | TABLET;ORAL | 021137-003 | Jun 6, 2003 | AB1,AB2,AB3,AB4 | RX | No | No | 10,231,931 | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| Genus Lifesciences | LEVOLET | levothyroxine sodium | TABLET;ORAL | 021137-007 | Jun 6, 2003 | AB1,AB2,AB3,AB4 | RX | No | No | 10,406,108 | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| Genus Lifesciences | LEVOLET | levothyroxine sodium | TABLET;ORAL | 021137-011 | Jun 6, 2003 | AB1,AB2,AB3,AB4 | RX | No | No | 10,406,108 | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
